Amgen Inc.
AMGNHealthcare Drug Manufacturers General
Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024.
- Revenue
- +8.45%
- EPS
- +19.4%
- Free cash flow
- −14.0%
- Total debt
- −1.06%
Quarter to September 2026, against a year earlier
Follow AMGN
Alert me
Amgen Inc. 10-Q filed Aug 6, 2025
What changed
Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 2, 2025: 26 added · 9 removed · 50 modified; 6 with only figures updated; 5 moved without change
-
Modified
The following MD&A is intended to assist the reader in understanding Amgen’s business. MD&A is provided as a supplement to, and should be read in conjunction with
, both the condensed consolidated financial statements and accompanying notes of this Quarterly Report on Form 10-Qour Annual Report on Form 10-K for the year ended December 31, 2024, and ourAnnualQuarterly Report on Form10-K10-Q for theyearquarter endedDecemberMarch 31,20242025. Our results of operations discussed in MD&A are presented in conformity with GAAP. Amgen operates in one operating segment: human therapeutics. Therefore, our results of operations are discussed on a consolidated basis.